Open AccessImmunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo
Author(s) -
Nicole A. Hoff,
Anna Bratcher,
John D. Kelly,
Kamy Musene,
Jean Paul Kompany,
Michel Kabamba Nzaji,
Placide MbalaKingebeni,
Bonnie Dighero-Kemp,
Gregory Kocher,
Elizabeth Elliott,
Cavan Reilly,
Megan Halbrook,
Benoit Kebela,
Adva Gadoth,
Guillaume Ngoie Mwamba,
Merly Tambu,
David R. McIlwain,
Patrick Mukadi,
Lisa E. Hensley,
Steve AhukaMundeke,
George W. Rutherford,
Jean Jacques Muyembe-Tamfum,
Anne W. Rimoin
Publication year - 2022
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2118895119
Subject(s) - ebola virus , medicine , ebola vaccine , vaccination , antibody , immunogenicity , virology , titer , immunology , antibody titer , outbreak , neutralizing antibody , cohort
Significance This paper describes findings from a seroepidemiologic study involving a cohort of Ebola-vaccinated individuals from North Kivu, Democratic Republic of the Congo (DRC), who were studied as part of a collaborative effort between American and Congolese scientists and epidemiologists. Our study examines antibody response at 21 d and 6 mo postvaccination after single-dose rVSVΔG-ZEBOV-GP vaccination among Ebola virus disease–exposed and potentially exposed populations in the DRC. At 21 d of follow-up, 87.2% had an antibody response. Additionally, 95.6% demonstrated antibody persistence at 6 mo of follow-up. These findings give crucial evidence that antibody response and persistence after Ebola vaccination is robust in outbreak settings in the DRC, knowledge that significantly informs the use of vaccination for outbreak control.